Published: Apr 19, 2021
MONTREAL, April 19, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma, Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dose (MTD) study in mice. Sunshine Biopharma is pleased to report that the MTD results are favorable and fall within the optimum range for use in humans. Next, Sunshine Biopharma will use the test dose indicated by these results to conduct the efficacy studies in hACE2-transgenic mice.
Sunshine Biopharma’s COVID-19 treatment is an inhibitor of PLpro, a protease present only in the SARS Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host innate immune system thereby causing significantly greater morbidity.
Corona in Braunschweig: Fakten, Krankheitssymptome, Virus
braunschweiger-zeitung.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from braunschweiger-zeitung.de Daily Mail and Mail on Sunday newspapers.
EQS-News: Relief veröffentlicht Finanzergebnisse für das Geschäftsjahr 2020 und gibt Update zur Unternehmensentwicklung
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.